Kedar Kirtane, MD, speaks on the unique mechanism of action of A2B530 and how the agent could represent a huge leap forward in the application of CAR T-cell agents for patients with solid tumors if the EVEREST-1 study proves to be positive.
Looking to replicate the impressive findings with CAR T-cell therapies observed in patients with hematologic malignancies, investigators have initiated the BASECAMP-1 trial with the hope of identifying patients with advanced solid tumors who will be suitable candidates for treatment in the EVEREST trial.
An op-ed, published in April in The Conversation, pointed to oral sex as the leading risk factor for throat cancer. The leading risk factor for all throat cancer in most developed countries is human papillomavirus (HPV), which can be transmitted via oral sex.